作者:Camila F. A. Sena、Lívia S. Apolinário、Jaqueline A. Duarte、Giovanna C. dos Santos、Liziane O. F. Monteiro、Mônica C. de Oliveira、Elaine A. Leite、Renata B. de Oliveira
DOI:10.1007/s11051-017-4073-6
日期:2017.11
administration. Degradation studies demonstrated that this compound is sensitive to hydrolysis. BNB was predicted to have a favorable absorption, distribution, metabolism, and excretion profile. The nanocarriers developed were characterized for particle size (PS = 61 to 85 nm), polydispersity index (PI < 0.3), zeta potential (ZP = − 22 to − 34 mV), and encapsulation efficiency (EE = 66 to 90%) and remained
该ñ-(丁酰氧基乙基)-4-(氯甲基)-3-硝基苯甲酰胺(BNB)是具有显着抗肿瘤活性的硝基芳香族衍生物。进行了预配制,强制降解(蒸馏水,酸和碱的水解,氧化和光照)和配方研究,以研究分子的化学行为,理化性质以及配方变量的影响。BNB的药代动力学特性已通过计算机估算。通过热熔均质化方法开发了含有BNB的固体脂质纳米颗粒(SLN)和纳米结构脂质载体(NLC),用于肠胃外给药。降解研究表明该化合物对水解敏感。预计BNB具有良好的吸收,分布,代谢和排泄特性。所开发的纳米载体的粒径(PS = 61至85 nm),多分散指数(PI <0.3),ζ电位(ZP = − 22至− 34 mV)和包封效率(EE = 66至90%)和保持稳定30天的存储。这些研究表明BNB(抑制浓度(IC50)21.8μM)和负载BNB的NLC(IC 50 33.7μM)对乳腺癌细胞系表现出中等的细胞毒性。空白制剂不会诱导细胞